Aquestive Therapeutics, Inc. AQST Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s total cost of revenue?
- Aquestive Therapeutics, Inc. (AQST) reported total cost of revenue of $3.47M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s total cost of revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s total cost of revenue decreased by 5.0% year-over-year, from $3.65M to $3.47M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s total cost of revenue?
- Over 3 years (2022 to 2025), Aquestive Therapeutics, Inc.'s total cost of revenue has grown at a -1.4% compound annual growth rate (CAGR), from $19.39M to $18.56M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.